Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 424-820-7 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1996
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study conducted to GLP standards and in accordance with OECD guideline 407 and EU method B.7. Some details on the test material are missing
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 996
- Report date:
- 1996
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Version / remarks:
- and OECD guideline 407.
- GLP compliance:
- yes
- Limit test:
- no
Test material
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories Inc. Kingston Facility, Stone Ridge, NY
- Age at study initiation: 7 weeks
- Weight at study initiation: Males 192.6-212.9 grams. Females 161.0-185.1 grams.
- Fasting period before study: Not stated
- Housing: Single house during the study period, suspended stainless steel and wire mesh with aborbent paper below cages.
- Diet: PMI Certified Rodent Diet Meal 5002 (ad libitum).
- Water: Automatic watering system (ad libitum)
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24.4
- Humidity (%): 40-70% relative humidity
- Air changes (per hr): Not stated
- Photoperiod (hrs dark / hrs light): 12 hours light (0700 to 1900 hours) and 12 hours dark (1900 to 0700 hours) by automatic timer.
IN-LIFE DATES: From: June 11, 1996 To: July 23, 1996
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
DIET PREPARATION
Test substance was dosed via oral gavage.
VEHICLE
- Corn Oil.
- Concentration in vehicle: 0, 10, 50 and 150 mg/kg of animal body weight.
- Amount of vehicle (if gavage): 5 ml/kg ( 7 days a week).
- Lot/batch no. (if required): SEP2096B and OCT2696B
- Purity: Not stated - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- SUMMARY: Samples of the test substance in corn oil were received by the Analytical Chemistry Laboratory for analysis. The samples were diluted with acetone and were analysed for uniformity, stability, and concentration verification using High Performance Liquid Chromatography (HPLC).
PREPERATION: Samples of the test substance in corn oil were received at nominal concentrations of 0.2, 1.0, and 3.0, and 15 % w/v from the Compound Preparation Department. Sample aliquots were diluted 2:10 or 2:50 with acetone. A corn oil control was diluted (simulating sample preparation) and analysed with each sample set.
STANDARDIZATION: A series of standards of the test substance diluted in acetone was prepared. The final concentrations of the standards bracketed the nominal diluted sample concentrations and a multi-point calibration was used to quantify the samples. - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- 7 days per week for a period of 4 weeks
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
10 mg/kg
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
50 mg/kg
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
150 mg/kg
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
150 mg/kg (satellite group, dosed for 28 days and then allowed to recover for 14 days)
Basis:
actual ingested
- No. of animals per sex per dose:
- 5 animals per sex per dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose levels were selected on the basis of two seperate rangefinding studies, as detailed in results section.
- Rationale for animal assignment: Random
- Rationale for selecting satellite groups: Dosed with high dose for 28 days and then allowed to recover for 14 days.
- Post-exposure recovery period in satellite groups: 14 days - Positive control:
- No positive control was included.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Twice daily monday to friday, once daily saturday and sunday.
- Cage side observations checked in table were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Once daily
BODY WEIGHT: Yes
- Time schedule for examinations: Day 0, 7, 14, 21 and 27 and on the day of death for all animals. Additionally body weights were recorded for the satellite animals on Days 35 and 41.
FOOD CONSUMPTION
-Food consumption was measured on Day 7, 14, 21 and 27 during the test period. Additionally food consumption was measured for the satellite animals on Days 35 and 41. Food consumption values for weeks 4 and 6 were based on a 6 day interval due to fasting of the animals on Day 27 and 41 for blood collection on Days 28 and 42, respectively.
OPHTHALMOSCOPIC EXAMINATION: No data
- Time schedule for examinations:
- Dose groups that were examined:
HAEMATOLOGY: Yes
- Time schedule for collection of blood: day 28 (Day 42 for satellite group)
- Anaesthetic used for blood collection: Yes (methoxyflurane)
- Animals fasted: Yes
- How many animals: All animals
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Day 28 (Day 42 for satellite group)
- Animals fasted: Yes
- How many animals: All animals
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no treatment related clinical signs of toxicity observed in any of the animals at any dose level tested. Observations were limited to a low incidence of dental abnormalities and/or red ocular discharge. One 10 mg/kg dose female was observed with red material around her snout on Day 21, but this finding was probably the result of maloccluded incisors. All findings were considered incidental and unrelated to treatment with the test material.
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- Unscheduled mortality was limited to one satellite female which died following an accidental injury. This death was not considered treatment-related. All
remaining animals survived to scheduled terminal sacrifice on Day 28 or Day 42 (satellite group). - Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no statistically significant differences in mean body weights between the treated and control animals of either sex. All animals displayed increases in body weight over their initial values. Mean body weight of the satellite animals (not included in statistical analysis) was comparable to controls and other treated groups.
Mean body weight gain was statistically significantly lower in the mid dose males compared with controls during the Day 2 1/27 interval. This difference was not considered toxicologically significant since body weight and weight gain were not affected at the high dose level. - Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- No statistically significant differences between mean food consumption between control and treated groups.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- There were no statistically significant differences in quantitative or semiquantitative hematological parameters between treated and control animals of either sex. In general, the mean hematological values of the satellite animals (not included in statistical analysis) were comparable to controls and/or other treated groups on Day 28.
Following the recovery period, there were several statistically significant but relatively small differences in quantitative hematological parameters in satellite group animals from Day 28 to Day 42. These changes included a statistically significant increase in mean red blood cells in males (6%), an increase in hematocrit in females (5%), and a decrease in mean corpuscular hemoglobin concentration (2%) in females. These small differences were not considered clinically significant. In addition, there were statistically significant differencesin semi-quantitative hematology parameters, including an increase in mean percentage of monocytes in males and females, and mean percentage and absolute eosinophils in females. In the absence of correlating findings at main study termination, these changes were considered incidental and unrelated to treatment. - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no differences in serum chemistry parameters between treated and control animals of either sex at main study termination which were considered the result of treatment with the test material. In general, the mean serum chemistry values of the satellite animals (not included in statistical analysis) were comparable to controls and/or other treated groups on Day 28.
There was a statistically significant decrease in mean calcium of the 50 mg/kg males at study termination compared with controls on Day 28. Additionally, there was a statistically significant decrease in mean blood urea nitrogen in the 150 mg/kg dose females. In the absence of other correlating fmdings, these difference were not considered clinically significant.
Following the recovery period, there were several statistically significant differences in serum chemistry parameters of the satellite group animals from Day 28 to Day 42. These included statistically significant increases in mean sodium (1%), albumin (3%), and total protein (4%) of the male animals, and mean calcium (5%), total protein (7%), and cholesterol (40%) of the female animals. In addition, there was a statistically significant decrease in mean phosphorous (12%) in the male animals from Day 28 to 42. These generally small differences were not considered clinically significant since they were limited to the recovery phase. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- There were no statistically significant differences in mean absolute organ weight, organ-to-body weight ratio, or organ-to-brain weight ratio between treated and control animals of either sex.
At the recovery group termination (Day 42), there were no statistically significant differences in mean organ-to-body or organ-to-brain weight ratios between the Day 42 satellite group weights and Day 28 control or high dose weights. - Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- The majority of animals were free of observable abnormalities at the postmortem examination. One female each in the 10, 50 and 150 mg/kg dose group was observed with whitened areas in the stomach.
There was a low incidence of ocular discharge and/or maloccluded incisors, and one satellite male was observed with small, flaccid testis. These findings were considered incidental and unrelated to treatment with the test material.
There were no significant postmortem findings in the one satellite animal which succumbed following an accidental injury. This death was not related to treatment with the test material. - Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Treatment-related microscopic changes were observed in the stomach of high dose (150 mg/kg) males and females. Microscopically, a minimal to moderate amount of submucosal edema and/or inflammation was observed in the forestomach of three male and four female rats of the high dose group. This change was characterized by a thickening of the submucosal area due to accumulation of edema fluid occasionally accompanied by a mostly polymorphonuclear inflammatory cell infiltration. There was no evidence of this change in any of the satellite animals following the 14 day recovery period.
No treatment-related microscopic changes were observed in any of the tissues examined from male and female rats of the low (10 mg/kg) or mid (50 mg/kg) dose groups. One other change observed at a very low incidence in the stomach was focal areas of submucosal edema/inflammation in the glandular area of the stomach. This was histologically different from the aforementioned treatmentrelated effect and was observed in only two control rats. - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- local
- Effect level:
- 50 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- histopathology: non-neoplastic
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- systemic
- Effect level:
- >= 150 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no systemic findngs up to highest dose tested
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Any other information on results incl. tables
RATIONALE FOR DOSE SELECTION
Dose levels for the 28 Day study (0, 10, 50, and 150 mg/kg) were selected based on the results of two separate dose rangefinding studies. In the first rangefinding study, the test material was administered to 2 rats/sex/group at dose levels of 100, 250, 500, and 1000 mg/kg. Both females in the 1000 mg/kg dose group were observed with adverse clinical signs (dyspnea, staining, soft stool, decreased food consumption, emaciation, rales, and/or poor condition) and subsequently died prior to scheduled termination (Day 7). Additionally, evidence of body weight gain suppression and decreased food consumption were observed in the 1000 mg/kg dose group. There were no significant findings at necropsy.
In the second rangefinding study, the test material was administered to 4 ratslsex/group at dose levels of 0, 50, 150, 500, and 1000 and mg/kg. All males and three of four females in the 1000 mg/kg group, and one male and one female in the 500 mg/kg group were observed with adverse clinical signs (dyspnea, staining, stool abnormalities, decreased food consumption, emaciation, rales, and/or poor condition etc.) and subsequently died prior to scheduled termination (Day 14). Additionally, evidence of body weight gain suppression and decreased food consumption was observed in the 1000 mg/kg dose group and possibly in the 500 mg/kg group. At necropsy, there was evidence of stomach irritation in one 50 mg/kg male, one 150 mg/kg female, four 500 mg/kg males, three 500 mg/kg females, and all 1000 mg/kg animals. The gross stomach changes ranged from roughened mucosa in the 50 and 150 mg/kg dose groups to more severe changes in the 1000 mg/kg dose group such as sloughing and discoloration of the mucosa. Thus, the severity of stomach effects appeared to be dose-dependent.
Together, the above rangefinding studies showed that dose levels 500 mg/kg were not acceptable for the 28 Day study due to lethality. Although no lethality occurred at levels<500 mg/kg over the course of one or two weeks of dosing, gross stomach lesions were observed at rangefinding levels as low as 50 mg/kg. Therefore, in consideration of the longer (4 week) dosing period of the main study, a high dose level of 150 mg/kg was considered appropriate to avoid lethality and minimize excessive stomach irritation.
ANALYTICAL CHEMISTRY
UNIFORMITY OF TEST SUBSTANCE IN CORN OIL
Sample ID |
Rep 1 |
Rep 2 |
Rep 3 |
Mean |
SD |
RSD |
0.2% |
0.144 |
0.132 |
0.117 |
0.131 |
0.0135 |
10.3% |
1.5% |
1.33 |
1.19 |
1.27 |
1.26 |
0.0702 |
5.6% |
15% |
15.9 |
16.1 |
15.6 |
15.9 |
0.252 |
1.58% |
STABILITY OF TEST SUBSTANCE IN CORN OIL
Sample ID |
Day 0 |
Day 2 |
% Change Day 0-2 |
0.2% |
0.131 |
0.132 |
+0.763% |
15% |
15.9 |
12.4 |
-22.0% |
Sample ID |
Day 0 |
Day 3 |
% Change Day 0-3 |
Day 6 |
% Change Day 0-6 |
0.2% |
0.206 |
0.174 |
-15.5% |
0.162 |
-21.4% |
3.0% |
3.08 |
2.31 |
-25.0% |
2.06 |
-33.1% |
Results are reported in % w/v.
CONCENTRATION VERIFICATION OF TEST SUBSTANCE IN CORN OIL
Sample ID |
Run 1 |
Run 2 |
0.2% |
0.206 |
0.208 |
1.0% |
1.26 |
10.4 |
3.0% |
3.08 |
2.74 |
Results are reported in % w/v.
Satisfactory uniformity was observed. The relative standard deviation ranged from 1.58% to 16.7%. The test material was shown to be stable at room temperature for at least 2 to 3 days. Concentration verification analyses indicated that the test material concentration was within 9% of the nominal value with the exception of the 1.0% week one sample which was 26% higher than the nominal value.
Applicant's summary and conclusion
- Conclusions:
- In conclusion, oral administration of the test material under conditions of this study elicited no signs of systemic toxicity. Treatment-related adverse effects were limited to local stomach irritation observed in the high dose (150 mg/kg) males and females which was reversible after a 14 day recovery period. There were no adverse effects with respect to clinical signs, body weights, body weight changes, food consumption, clinical parameters, or organ weights. Based on the microscopic changes observed in the stomachs at the high dose level, a No Observable Adverse Effect Level (NOAEL) for local effects was established at 50 mg/kg of the test material in both males and females. Excluding microscopic effects in the forestomach attributed to the irritant nature of the test material, a systemic NOAEL in males and female rats would be 150 mg/kg.
No circumstances occurred that would have affected the quality or integrity of the data. - Executive summary:
This study was conducted to evaluate the potential toxicity of the test material when administered orally by gavage to rats for a period of 28 days. The study consisted of a carrier control (corn oil) group, three experimental groups, and a satellite recovery group. All groups contained 5 male and 5 female rats. Prior to start of the study, two separate dose rangefinding studies were conducted for the purpose of dose level selection. Based on results of the rangefinding studies, dose levels of 10,50,and 150 mg/kg were selected for the 28 Day study (a high dose level of 150 mg/kg was selected to avoid lethality and minimize excessive stomach irritation). Individual doses were adjusted weekly based on the most recent body weights. Satellite group animals were treated with the test material for 28 days at 150 mg/kg and then observed for an additional period of 14 days for reversibility, persistence or delayed occurrence of toxic effects.
Clinical observations were performed daily throughout the study. Body weights were recorded at pretest, at dose initiation (Day 0), on Days 7, 14, 21 and 27, on the day of death, and on Days 35 and 41 for satellite animals. Food consumption was measured weekly. Hematology and serum chemistry studies were performed on all animals on Day 28 and on all surviving satellite animals on Day 42. A full macroscopic postmortem examination was performed on all animals and required organs were preserved. Selected organs were weighed at study termination and a range of tissues was examined microscopically. The microscopic examination was extended to the stomachs of all rats based on the known irritating properties of the test material and on the presence of gross stomach lesions in a few rats at necropsy.
There were no treatment-related deaths during the study. Unscheduled mortality was limited to one satellite female which died following an accidental injury on Day 23. All remaining animals survived to scheduled sacrifice on Day 28 or 42 (satellite group).
No treatment-related clinical signs of toxicity were observed and there were no statistically significant and/or biologically meaningful differences among the groups with respect to mean body weights, body weight gain, food consumption, hematological parameters, serum chemistry parameters, absolute organ weights, organ-to-body weight ratios, or organ-to-brain weight ratios. Similarly, there were no meaningful changes in these parameters following the recovery period.
There were no gross or microscopic observations indicative of a systemic toxic effect of the test material. Gross stomach lesions were observed in one female each in the 10, 50 and 150 mg/kg dose groups. However, treatment-related microscopic findings were limited to 150 mg/kg males and females and characterized by submucosal edema and/or inflammation of the forestomach. These changes were not observed in the satellite animals following the 14 day recovery period indicating that this change was reversible.
In conclusion, oral administration of the test material under conditions of this study elicited no signs of systemic toxicity. Treatment-related adverse effects were limited to local stomach irritation observed in the high dose (150 mg/kg) males and females which was reversible after a 14 day recovery period. There were no adverse effects with respect to clinical signs, body weights, body weight changes, food consumption, clinical parameters, or organ weights. Based on the microscopic changes observed in the stomachs at the high dose level, a No Observable Adverse Effect Level (NOAEL) was established for local effects at 50 mg/kg of the test material in both males and females. Excluding microscopic effects in the forestomach attributed to the irritant nature of the test material, a systemic NOAEL in males and female rats would be 150 mg/kg.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Vi har mycket webbmaterial på ditt språk, men en del av den här sidan finns bara på engelska. Mer om vår flerspråkighetspolicy finns.
Välkommen till Echas webbplats. Alla funktioner på den här webbplatsen fungerar inte med Internet Explorer 7 (eller tidigare versioner). Det är därför bäst att du uppgraderar till en nyare version.
På den här webbplatsen används kakor. Syftet är att optimera din upplevelse av den.
Läs mer om hur vi använder kakor.